

References

- Adji, A.S., Widjaja, J.S. and de Liyis, B.G. (2024) “Effectiveness and safety of mineralocorticoid receptor antagonists in heart failure patients with and without diabetes: a systematic review and meta-analysis.” *The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology*, 76(1), p. 150. Available at: <https://doi.org/10.1186/s43044-024-00580-5>.
- Alfieri, V. *et al.* (2021) “The Role of Glycemic Variability in Cardiovascular Disorders.” *International journal of molecular sciences*, 22(16). Available at: <https://doi.org/10.3390/ijms22168393>.
- Al-Khadra, A.S. *et al.* (1998) “Antiplatelet Agents and Survival: A Cohort Analysis From the Studies of Left Ventricular Dysfunction (SOLVD) Trial,” *Journal of the American College of Cardiology*, 31(2), pp. 419–425. Available at: [https://doi.org/10.1016/S0735-1097\(97\)00502-0](https://doi.org/10.1016/S0735-1097(97)00502-0).
- Alzahri, M.S., Rohra, A. and Peacock, W.F. (2016) “Nitrates as a Treatment of Acute Heart Failure.” *Cardiac failure review*, 2(1), pp. 51–55. Available at: <https://doi.org/10.15420/cfr.2016:3:3>.
- Angiolillo, D.J. (2009) “Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions.” *Diabetes care*, 32(4), pp. 531–40. Available at: <https://doi.org/10.2337/dc08-2064>.
- Anker, S.D. *et al.* (2023) “Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension,” *European Journal of Heart Failure*, 25(7), pp. 936–955. Available at: <https://doi.org/10.1002/ejhf.2894>.
- Belli, M. *et al.* (2023) “Glucose variability: a new risk factor for cardiovascular disease.” *Acta diabetologica*, 60(10), pp. 1291–1299. Available at: <https://doi.org/10.1007/s00592-023-02097-w>.
- Blagov, A. V *et al.* (2023) “Interventional Cardiology Mechanisms of ischemic heart disease development in diabetes mellitus,” *Interv. Cardiol*, 15, pp. 697–705. Available at: <https://doi.org/10.37532/1755>.
- Bonacchi, G. *et al.* (2024) “Pathophysiological Link and Treatment Implication of Heart Failure and Preserved Ejection Fraction in Patients with Chronic Kidney Disease.” *Biomedicines*, 12(5). Available at: <https://doi.org/10.3390/biomedicines12050981>.

- Bursac, Z. *et al.* (2008) "Purposeful selection of variables in logistic regression.," *Source code for biology and medicine*, 3, p. 17. Available at: <https://doi.org/10.1186/1751-0473-3-17>.
- Camafort, M., Sepulveda, C. and Viñas, E. (2025) *Hypertension and heart failure, a dangerous relationship*, [https://www.escardio.org/Councils/Council-for-Cardiology-Practice-\(CCP\)/Cardiopactice/hypertension-and-heart-failure-a-dangerous-relationship](https://www.escardio.org/Councils/Council-for-Cardiology-Practice-(CCP)/Cardiopactice/hypertension-and-heart-failure-a-dangerous-relationship).
- Catalá-López, F. *et al.* (2016) "Cardiovascular and Renal Outcomes of Renin–Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses," *PLOS Medicine*, 13(3), p. e1001971. Available at: <https://doi.org/10.1371/journal.pmed.1001971>.
- Chang, J. *et al.* (2024) "Mineralocorticoid Antagonism in Heart Failure," *JACC: Heart Failure*, 12(12), pp. 1979–1993. Available at: <https://doi.org/10.1016/j.jchf.2024.08.007>.
- Chen, S. *et al.* (2023) "Effects of β -blockers on all-cause mortality in patients with diabetes and coronary heart disease: A systematic review and meta-analysis," *Frontiers in Cell and Developmental Biology*, 11. Available at: <https://doi.org/10.3389/fcell.2023.1076107>.
- Chen, Y.-H. *et al.* (2025) "Nonsteroidal mineralocorticoid receptor antagonists and cardiovascular events in type 2 diabetes: a retrospective study," *European Heart Journal - Cardiovascular Pharmacotherapy* [Preprint]. Available at: <https://doi.org/10.1093/ehjcvp/pvaf048>.
- Chen, Z. *et al.* (2022) "Phosphodiesterase inhibitor for heart failure with preserved ejection fraction: A systematic review and meta-analysis.," *Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society*, 30(8), pp. 1079–1087. Available at: <https://doi.org/10.1016/j.jsps.2022.05.012>.
- Cheng, J. *et al.* (2014) "Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality, Cardiovascular Deaths, and Cardiovascular Events in Patients With Diabetes Mellitus," *JAMA Internal Medicine*, 174(5), p. 773. Available at: <https://doi.org/10.1001/jamainternmed.2014.348>.
- Chowdhury, M.Z.I. and Turin, T.C. (2020) "Variable selection strategies and its importance in clinical prediction modelling," *Family Medicine and Community Health*, 8(1), p. e000262. Available at: <https://doi.org/10.1136/fmch-2019-000262>.

- Christersson, M. *et al.* (2024) “Usefulness of Heart Failure Categories Based on Left Ventricular Ejection Fraction,” *Journal of the American Heart Association*, 13(8), p. e032257. Available at: <https://doi.org/10.1161/JAHA.123.032257>.
- Chun, K.H. *et al.* (2022) “In-hospital glycemic variability and all-cause mortality among patients hospitalized for acute heart failure,” *Cardiovascular Diabetology*, 21(1). Available at: <https://doi.org/10.1186/s12933-022-01720-4>.
- Danne, T. *et al.* (2017) “International consensus on use of continuous glucose monitoring,” *Diabetes Care*, 40(12), pp. 1631–1640. Available at: <https://doi.org/10.2337/dc17-1600>.
- Dhore-Patil, A. *et al.* (2021) “Diabetes Mellitus and Heart Failure With Preserved Ejection Fraction: Role of Obesity.,” *Frontiers in physiology*, 12, p. 785879. Available at: <https://doi.org/10.3389/fphys.2021.785879>.
- Dzhun, Y. *et al.* (2023) “Glycemic variability is associated with diastolic dysfunction in patients with type 2 diabetes,” *Journal of Diabetes and its Complications*, 37(11). Available at: <https://doi.org/10.1016/j.jdiacomp.2023.108519>.
- Echouffo-Tcheugui, J.B. *et al.* (2019) “Visit-to-visit glycemic variability and risks of cardiovascular events and all-cause mortality: The ALLHAT study,” *Diabetes Care*, 42(3), pp. 486–493. Available at: <https://doi.org/10.2337/dc18-1430>.
- Elnour, A.A. *et al.* (2023) “Mini review: The clinical avenues of combined hydralazine-nitrate in subjects with heart failure with reduced ejection fraction,” *Pharmacy Practice*. Grupo de Investigacion en Atencion Farmaceutica. Available at: <https://doi.org/10.18549/PharmPract.2023.2.2824>.
- Fukuta, H., Goto, T. and Kamiya, T. (2024) “Effects of calcium channel blockers in patients with heart failure with preserved and mildly reduced ejection fraction: A systematic review and meta-analysis,” *IJC Heart & Vasculature*, 55, p. 101515. Available at: <https://doi.org/10.1016/j.ijcha.2024.101515>.
- Fularska, K. *et al.* (2023) “Beta-blockers used in cardiac failure and blood glucose level impairment - a literature review,” *Journal of Education, Health and Sport*, 23(1), pp. 40–51. Available at: <https://doi.org/10.12775/JEHS.2023.23.01.005>.
- Gallo, G. and Savoia, C. (2024) “Hypertension and Heart Failure: From Pathophysiology to Treatment.,” *International journal of molecular sciences*, 25(12). Available at: <https://doi.org/10.3390/ijms25126661>.
- Gerbaud, E. *et al.* (2019) “Glycemic variability is a powerful independent predictive factor of midterm major adverse cardiac events in patients with diabetes with acute coronary

- syndrome,” *Diabetes Care*, 42(4), pp. 674–681. Available at: <https://doi.org/10.2337/dc18-2047>.
- Ghasemi, A. and Zahediasl, S. (2012) “Normality tests for statistical analysis: a guide for non-statisticians,” *International journal of endocrinology and metabolism*, 10(2), pp. 486–9. Available at: <https://doi.org/10.5812/ijem.3505>.
- Goldney, J. *et al.* (2024) “Age at onset of type 2 diabetes and prevalence of vascular disease and heart failure: Systematic review and dose-response meta-analysis,” *Journal of Diabetes and its Complications*, 38(10), p. 108849. Available at: <https://doi.org/10.1016/j.jdiacomp.2024.108849>.
- Gómez, A.M. *et al.* (2018) “Different Indexes of Glycemic Variability as Identifiers of Patients with Risk of Hypoglycemia in Type 2 Diabetes Mellitus,” *Journal of Diabetes Science and Technology*, 12(5), pp. 1007–1015. Available at: <https://doi.org/10.1177/1932296818758105>.
- Gorst, C. *et al.* (2015) “Long-term glycemic variability and risk of adverse outcomes: A systematic review and meta-analysis,” *Diabetes Care*, 38(12), pp. 2354–2369. Available at: <https://doi.org/10.2337/dc15-1188>.
- Gu, J. *et al.* (2018) “Prognostic impact of HbA1c variability on long-term outcomes in patients with heart failure and type 2 diabetes mellitus,” *Cardiovascular diabetology*, 17(1), p. 96. Available at: <https://doi.org/10.1186/s12933-018-0739-3>.
- Gurbel, P.A. and Tantry, U.S. (2014) “Antiplatelet and Anticoagulant Agents in Heart Failure,” *JACC: Heart Failure*, 2(1), pp. 1–14. Available at: <https://doi.org/10.1016/j.jchf.2013.07.007>.
- El Hadj Othmane, T., El Hadj Othmane, O. and Nizar, H. (2025) “Obesity-Related Phenotype of Heart Failure With Preserved Ejection Fraction: A Comprehensive Review,” *Cureus*, 17(3), p. e81512. Available at: <https://doi.org/10.7759/cureus.81512>.
- Hanajima, Y. *et al.* (2023) “Prognostic importance of glycemic variability on left ventricular reverse remodeling after the first episode of ST-segment elevation myocardial infarction,” *Cardiovascular Diabetology*, 22(1). Available at: <https://doi.org/10.1186/s12933-023-01931-3>.
- Harada, T. and Obokata, M. (2020) “Obesity-Related Heart Failure with Preserved Ejection Fraction,” *Heart Failure Clinics*, 16(3), pp. 357–368. Available at: <https://doi.org/10.1016/j.hfc.2020.02.004>.
- Heidenreich, P.A. *et al.* (2022) “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart

- Association Joint Committee on Clinical Practice Guidelines,” *Circulation*. Lippincott Williams and Wilkins, pp. E895–E1032. Available at: <https://doi.org/10.1161/CIR.0000000000001063>.
- Herman, L.L. *et al.* (2023) *Angiotensin-Converting Enzyme Inhibitors (ACEI)*. Treasure Island (FL): StatPearls Publishing.
- Hirakawa, Y. *et al.* (2014) “Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: The ADVANCE trial,” *Diabetes Care*, 37(8), pp. 2359–2365. Available at: <https://doi.org/10.2337/dc14-0199>.
- Hsu, J.-C. *et al.* (2025) “Long-Term Glycemic Variability Predicts Adverse Outcomes in Diabetic Heart Failure With Preserved Ejection Fraction,” *The Journal of Clinical Endocrinology & Metabolism*, 110(7), pp. 1929–1937. Available at: <https://doi.org/10.1210/clinem/dgae715>.
- Huang, Y. *et al.* (2025) “Systematic review and meta-analysis of nitrates/nitrites in patients with heart failure or pulmonary hypertension.,” *European journal of medical research*, 30(1), p. 661. Available at: <https://doi.org/10.1186/s40001-025-02916-6>.
- Jia, G., DeMarco, V.G. and Sowers, J.R. (2016) “Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy,” *Nature Reviews Endocrinology*, 12(3), pp. 144–153. Available at: <https://doi.org/10.1038/nrendo.2015.216>.
- Johansson, I. *et al.* (2016) “Prognostic Implications of Type 2 Diabetes Mellitus in Ischemic and Nonischemic Heart Failure,” *Journal of the American College of Cardiology*, 68(13), pp. 1404–1416. Available at: <https://doi.org/10.1016/j.jacc.2016.06.061>.
- Ke, C. *et al.* (2024) “Association Between Age at Diagnosis of Type 2 Diabetes and Hospitalization for Heart Failure: A Population-Based Study.,” *Journal of the American Heart Association*, 13(3), p. e030683. Available at: <https://doi.org/10.1161/JAHA.123.030683>.
- Kenny, H.C. and Abel, E.D. (2019) “Heart Failure in Type 2 Diabetes Mellitus: Impact of Glucose-Lowering Agents, Heart Failure Therapies, and Novel Therapeutic Strategies,” *Circulation Research*. Lippincott Williams and Wilkins, pp. 121–141. Available at: <https://doi.org/10.1161/CIRCRESAHA.118.311371>.
- Kim, W.J.C. *et al.* (2022) “Beyond Simpson’s Rule: Accounting for Orientation and Ellipticity Assumptions,” *Ultrasound in Medicine and Biology*, 48(12), pp. 2476–2485. Available at: <https://doi.org/10.1016/j.ultrasmedbio.2022.07.013>.

- Klaeboe, L.G. and Edvardsen, T. (2019) “Echocardiographic assessment of left ventricular systolic function,” *Journal of Echocardiography*. Springer Tokyo, pp. 10–16. Available at: <https://doi.org/10.1007/s12574-018-0405-5>.
- Kusunose, K. *et al.* (2022) “How to standardize the measurement of left ventricular ejection fraction,” *Journal of Medical Ultrasonics*. Springer, pp. 35–43. Available at: <https://doi.org/10.1007/s10396-021-01116-z>.
- Laakso, M. and Fernandes Silva, L. (2023) “Statins and risk of type 2 diabetes: mechanism and clinical implications.,” *Frontiers in endocrinology*, 14, p. 1239335. Available at: <https://doi.org/10.3389/fendo.2023.1239335>.
- Lahoz, R. *et al.* (2022) “Recurrent heart failure hospitalizations increase the risk of mortality in heart failure patients with atrial fibrillation and type 2 diabetes mellitus in the United Kingdom: a retrospective analysis of Clinical Practice Research Datalink database,” *BMC Cardiovascular Disorders*, 22(1), p. 234. Available at: <https://doi.org/10.1186/s12872-022-02665-y>.
- Leander, D.J. and Tahapary, D.L. (2021) “Pemilihan Obat Antidiabetik Oral pada Pasien Diabetes Melitus Tipe 2 dengan Risiko Tinggi untuk Kejadian Kardiovaskular,” *Jurnal Penyakit Dalam Indonesia*, 7(4), p. 240. Available at: <https://doi.org/10.7454/jpdi.v7i4.292>.
- Lee, D.Y. (2022) “Obesity and heart failure with preserved ejection fraction: pathophysiology and clinical significance,” *Cardiovascular Prevention and Pharmacotherapy*, 4(2), pp. 70–74. Available at: <https://doi.org/10.36011/cpp.2022.4.e10>.
- Lejeune, S. *et al.* (2021) “Diabetic phenotype and prognosis of patients with heart failure and preserved ejection fraction in a real life cohort.,” *Cardiovascular diabetology*, 20(1), p. 48. Available at: <https://doi.org/10.1186/s12933-021-01242-5>.
- Leone, D. *et al.* (2025) “Heart failure with preserved ejection fraction: from echocardiographic characteristics to a cardiovascular damage score in a high-risk hypertensive population,” *Journal of Hypertension*, 43(4), pp. 606–614. Available at: <https://doi.org/10.1097/HJH.0000000000003942>.
- Leopoulou, M. *et al.* (2023) “Diabetes mellitus and atrial fibrillation-from pathophysiology to treatment.,” *World journal of diabetes*, 14(5), pp. 512–527. Available at: <https://doi.org/10.4239/wjd.v14.i5.512>.

- Li, P. *et al.* (2021) “Similarities and Differences Between HFmrEF and HFpEF,” *Frontiers in Cardiovascular Medicine*, 8. Available at: <https://doi.org/10.3389/fcvm.2021.678614>.
- Lind, M. *et al.* (2012) “The relationship between glycaemic control and heart failure in 83,021 patients with type 2 diabetes,” *Diabetologia*, 55(11), pp. 2946–2953. Available at: <https://doi.org/10.1007/s00125-012-2681-3>.
- Löfström, U. *et al.* (2019) “Prognostic impact of Framingham heart failure criteria in heart failure with preserved ejection fraction,” *ESC Heart Failure*, 6(4), pp. 830–839. Available at: <https://doi.org/10.1002/ehf2.12458>.
- Longo, M. *et al.* (2021) “Mediterranean diet in type 2 diabetes: An updated overview of pharmacological activities of cardiometabolic and reproductive outcomes,” *Current Opinion in Pharmacology*. Elsevier Ltd, pp. 27–33. Available at: <https://doi.org/10.1016/j.coph.2021.06.005>.
- Longo, M. *et al.* (2022) “Glycemic Control and the Heart: The Tale of Diabetic Cardiomyopathy Continues,” *Biomolecules*. MDPI. Available at: <https://doi.org/10.3390/biom12020272>.
- Maheswara Satya G., G. and Shams, P. (2024) *Heart Failure With Preserved Ejection Fraction (HFpEF)*. Treasure Island (FL): StatPearls Publishing.
- Maiuolo, J. *et al.* (2021) “Effects of bergamot polyphenols on mitochondrial dysfunction and sarcoplasmic reticulum stress in diabetic cardiomyopathy,” *Nutrients*. MDPI. Available at: <https://doi.org/10.3390/nu13072476>.
- Martinez, M. *et al.* (2021) “Glycemic variability and cardiovascular disease in patients with type 2 diabetes,” *BMJ Open Diabetes Research and Care*. BMJ Publishing Group. Available at: <https://doi.org/10.1136/bmjdr-2020-002032>.
- Maru, S. *et al.* (2005) “Antidiabetic Drugs and Heart Failure Risk in Patients With Type 2 Diabetes in the U.K. Primary Care Setting,” *Diabetes Care*, 28(1), pp. 20–26. Available at: <https://doi.org/10.2337/diacare.28.1.20>.
- Masarone, D. *et al.* (2021) “The Use of β -Blockers in Heart Failure with Reduced Ejection Fraction,” *Journal of cardiovascular development and disease*, 8(9). Available at: <https://doi.org/10.3390/jcdd8090101>.
- Matsumoto, C. *et al.* (2022) “Incidence of atrial fibrillation in elderly patients with type 2 diabetes mellitus,” *BMJ Open Diabetes Research & Care*, 10(2), p. e002745. Available at: <https://doi.org/10.1136/bmjdr-2021-002745>.

- McKee, P.A. *et al.* (1971) “The Natural History of Congestive Heart Failure: The Framingham Study,” *New England Journal of Medicine*, 285(26), pp. 1441–1446. Available at: <https://doi.org/10.1056/NEJM197112232852601>.
- McKeever, R.G., Patel, P. and Hamilton, R.J. (2024) *Calcium Channel Blockers*. Treasure Island (FL): StatPearls Publishing.
- Mehrabani-Zeinabad, K. *et al.* (2023) “Impact of diabetes phenotype on cardiovascular diseases, major cardiovascular events and all-cause mortality,” *Scientific Reports*, 13(1), p. 11266. Available at: <https://doi.org/10.1038/s41598-023-38221-7>.
- Messerli, F.H. *et al.* (2018) “Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use?,” *Journal of the American College of Cardiology*. Elsevier USA, pp. 1474–1482. Available at: <https://doi.org/10.1016/j.jacc.2018.01.058>.
- Mishra, P. *et al.* (2019) “Descriptive statistics and normality tests for statistical data,” *Annals of cardiac anaesthesia*, 22(1), pp. 67–72. Available at: https://doi.org/10.4103/aca.ACA_157_18.
- Mukti, B.H. (2025) “Sample size determination: Principles and applications for health research,” *Health Sciences International Journal*, 3(1), pp. 127–143. Available at: <https://doi.org/10.71357/hsij.v3i1.63>.
- Narziev, B. *et al.* (2022) “Interventional Cardiology Potential triggers of atrial fibrillation in type 2 diabetes mellitus,” *Interv. Cardiol*, 12, pp. 311–318. Available at: <https://doi.org/10.37532/1755>.
- Nusca, A. *et al.* (2018) “Glycemic variability in the development of cardiovascular complications in diabetes,” *Diabetes/Metabolism Research and Reviews*, 34(8), p. e3047. Available at: <https://doi.org/https://doi.org/10.1002/dmrr.3047>.
- Packer, M. (2018) “Are the effects of drugs to prevent and to treat heart failure always concordant? The statin paradox and its implications for understanding the actions of antidiabetic medications,” *European Journal of Heart Failure*, 20(7), pp. 1100–1105. Available at: <https://doi.org/10.1002/ejhf.1183>.
- Palazzuoli, A. and Beltrami, M. (2021) “Are HFpEF and HFmrEF So Different? The Need to Understand Distinct Phenotypes,” *Frontiers in Cardiovascular Medicine*, 8. Available at: <https://doi.org/10.3389/fcvm.2021.676658>.
- Pareek, A.K. *et al.* (2017) “Diabetic Hypertensives and Diastolic Dysfunction,” *JACC: Heart Failure*, 5(11), pp. 850–851. Available at: <https://doi.org/10.1016/j.jchf.2017.08.003>.

- Park, C.S. *et al.* (2021) “Determinants of the survival benefit associated with statins in patients with acute heart failure.,” *ESC heart failure*, 8(6), pp. 5424–5435. Available at: <https://doi.org/10.1002/ehf2.13637>.
- Park, J.J. (2021) “Epidemiology, Pathophysiology, Diagnosis and Treatment of Heart Failure in Diabetes.,” *Diabetes & metabolism journal*, 45(2), pp. 146–157. Available at: <https://doi.org/10.4093/dmj.2020.0282>.
- Patel, P. and Launico, M. V. (2025) *Angiotensin II Receptor Blockers (ARB)*. Treasure Island (FL): StatPearls Publishing.
- Patel, R.N. *et al.* (2023) “Heart Failure With Preserved Ejection Fraction With CKD: A Narrative Review of a Multispecialty Disorder.,” *Kidney medicine*, 5(12), p. 100705. Available at: <https://doi.org/10.1016/j.xkme.2023.100705>.
- Pei, J. *et al.* (2023) “Glycemic control, HbA1c variability, and major cardiovascular adverse outcomes in type 2 diabetes patients with elevated cardiovascular risk: insights from the ACCORD study.,” *Cardiovascular diabetology*, 22(1), p. 287. Available at: <https://doi.org/10.1186/s12933-023-02026-9>.
- Pellicori, P. *et al.* (2021) “Use of diuretics and outcomes in patients with type 2 diabetes: findings from the <scp>EMPA-REG OUTCOME</scp> trial,” *European Journal of Heart Failure*, 23(7), pp. 1085–1093. Available at: <https://doi.org/10.1002/ejhf.2220>.
- PERKENI (2021) *Pedoman Pengelolaan dan Pencegahan Diabetes Mellitus tipe 2 di Indonesia 2021*.
- Perone, F. *et al.* (2024) “Obesity and cardiovascular disease: Risk assessment, physical activity, and management of complications,” *International Journal of Cardiology Cardiovascular Risk and Prevention*, 23, p. 200331. Available at: <https://doi.org/10.1016/j.ijcrp.2024.200331>.
- Preiss, D. *et al.* (2015) “The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials,” *European Heart Journal*, 36(24), pp. 1536–1546. Available at: <https://doi.org/10.1093/eurheartj/ehv072>.
- Psoma, O. *et al.* (2024) “Short-term Glycemic Variability and Its Association With Macrovascular and Microvascular Complications in Patients With Diabetes,” *Journal of Diabetes Science and Technology*, 18(4), pp. 956–967. Available at: <https://doi.org/10.1177/19322968221146808>.
- Reyna, J. *et al.* (2013) “Combined phosphodiesterase inhibitors in end-stage heart failure: A case presentation,” *World Journal of Cardiovascular Diseases*, 03(03), pp. 266–267. Available at: <https://doi.org/10.4236/wjcd.2013.33042>.

- Rodriguez-Araujo, G. and Nakagami, H. (2018) "Pathophysiology of cardiovascular disease in diabetes mellitus.," *Cardiovascular endocrinology & metabolism*, 7(1), pp. 4–9. Available at: <https://doi.org/10.1097/XCE.000000000000141>.
- Royston, J.P. (1982) "An Extension of Shapiro and Wilk's W Test for Normality to Large Samples," *Applied Statistics*, 31(2), p. 115. Available at: <https://doi.org/10.2307/2347973>.
- Schejter, Y.D., Turvall, E. and Ackerman, Z. (2012) "Characteristics of Patients With Sulphonurea-Induced Hypoglycemia," *Journal of the American Medical Directors Association*, 13(3), pp. 234–238. Available at: <https://doi.org/https://doi.org/10.1016/j.jamda.2010.07.014>.
- Schiller, N.B. *et al.* (1989) "Recommendations for Quantitation of the Left Ventricle by Two-Dimensional Echocardiography," *Journal of the American Society of Echocardiography*, 2(5), pp. 358–367. Available at: [https://doi.org/https://doi.org/10.1016/S0894-7317\(89\)80014-8](https://doi.org/https://doi.org/10.1016/S0894-7317(89)80014-8).
- Schwinger, R.H.G. (2021) "Pathophysiology of heart failure," *Cardiovascular Diagnosis and Therapy*. AME Publishing Company. Available at: <https://doi.org/10.21037/CDT-20-302>.
- Segar, M.W. *et al.* (2020) "Association of long-term change and variability in glycemia with risk of incident heart failure among patients with type 2 diabetes: A secondary analysis of the ACCORD trial," *Diabetes Care*, 43(8), pp. 1920–1928. Available at: <https://doi.org/10.2337/dc19-2541>.
- Shibata, M. *et al.* (2010) *Do calcium channel blockers increase the diagnosis of heart failure in patients with hypertension?* Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. York (UK): Centre for Reviews and Dissemination (UK).
- Shorikov, E.I. and Shorikova, D. V. (2022) *Phenotypes of arterial hypertension in patients with diabetes mellitus type 2: orthostatic hypotension and daily variability of blood pressure*, <https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-22/phenotypes-of-arterial-hypertension-in-patients-with-diabetes-mellitus-type-2-o>.
- Sincer, I. (2025) "A comprehensive review on diabetes mellitus and heart failure," *Exploration of Endocrine and Metabolic Diseases*, 2. Available at: <https://doi.org/10.37349/eemd.2025.101435>.
- Singh, B. *et al.* (2025) *ACE Inhibitors*. Treasure Island (FL): StatPearls Publishing.

- Slivnick, J. and Lampert, B.C. (2019) "Hypertension and Heart Failure," *Heart Failure Clinics*. Elsevier Inc., pp. 531–541. Available at: <https://doi.org/10.1016/j.hfc.2019.06.007>.
- Smiseth, O.A. *et al.* (2023) "Phenotyping heart failure by echocardiography: imaging of ventricular function and haemodynamics at rest and exercise," *European Heart Journal Cardiovascular Imaging*. Oxford University Press, pp. 1329–1342. Available at: <https://doi.org/10.1093/ehjci/jead196>.
- Soroush, N. *et al.* (2024) "Statin therapy and cardiovascular protection in type 2 diabetes: The role of baseline LDL-Cholesterol levels. A systematic review and meta-analysis of observational studies," *Nutrition, Metabolism and Cardiovascular Diseases*, 34(9), pp. 2021–2033. Available at: <https://doi.org/10.1016/j.numecd.2024.04.015>.
- Souza, R.R. de *et al.* (2023) "Sample size and Shapiro-Wilk test: An analysis for soybean grain yield," *European Journal of Agronomy*, 142, p. 126666. Available at: <https://doi.org/10.1016/j.eja.2022.126666>.
- Umpierrez, G.E. and P. Kovatchev, B. (2018) "Glycemic Variability: How to Measure and Its Clinical Implication for Type 2 Diabetes," *American Journal of the Medical Sciences*. Elsevier B.V., pp. 518–527. Available at: <https://doi.org/10.1016/j.amjms.2018.09.010>.
- Varma, A., Shah, K.B. and Hess, M.L. (2012) "Phosphodiesterase Inhibitors, Congestive Heart Failure, and Sudden Death: Time for Re-Evaluation," *Congestive Heart Failure*, 18(4), pp. 229–233. Available at: <https://doi.org/10.1111/j.1751-7133.2012.00293.x>.
- Vicent, L. *et al.* (2023) "Coronary Artery Disease and Prognosis of Heart Failure with Reduced Ejection Fraction.," *Journal of clinical medicine*, 12(8). Available at: <https://doi.org/10.3390/jcm12083028>.
- Vijay, K., Neuen, B.L. and Lerma, E. V. (2022) "Heart Failure in Patients with Diabetes and Chronic Kidney Disease: Challenges and Opportunities," *Cardiorenal Medicine*, 12(1), pp. 1–10. Available at: <https://doi.org/10.1159/000520909>.
- Vitarelli, A. and Gheorghide, M. (2000) "Transthoracic and transesophageal echocardiography in the hemodynamic assessment of patients with congestive heart failure," *The American Journal of Cardiology*, 86(4, Supplement 1), pp. 36–40. Available at: [https://doi.org/https://doi.org/10.1016/S0002-9149\(00\)00990-5](https://doi.org/https://doi.org/10.1016/S0002-9149(00)00990-5).
- Weeda, E.R. *et al.* (2019) "Loop diuretic use among patients with heart failure and type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors.," *Journal of diabetes*

- and its complications*, 33(8), pp. 567–571. Available at: <https://doi.org/10.1016/j.jdiacomp.2019.05.001>.
- WHO (2025) *Cardiovascular diseases (CVDs)*. Available at: [https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-\(cvds\)](https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)) (Accessed: September 7, 2025).
- Wijnen, M. *et al.* (2022) “The effects of antidiabetic agents on heart failure.,” *Netherlands heart journal: monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation*, 30(2), pp. 65–75. Available at: <https://doi.org/10.1007/s12471-021-01579-2>.
- van de Wouw, J. *et al.* (2019) “Chronic Kidney Disease as a Risk Factor for Heart Failure With Preserved Ejection Fraction: A Focus on Microcirculatory Factors and Therapeutic Targets,” *Frontiers in Physiology*, 10. Available at: <https://doi.org/10.3389/fphys.2019.01108>.
- Xanthopoulos, A. *et al.* (2023) “Heart Failure in Patients with Chronic Kidney Disease.,” *Journal of clinical medicine*, 12(18). Available at: <https://doi.org/10.3390/jcm12186105>.
- Yang, C.D. *et al.* (2023) “Long-term glycemic variability predicts compromised development of heart failure with improved ejection fraction: a cohort study.,” *Frontiers in endocrinology*, 14, p. 1211954. Available at: <https://doi.org/10.3389/fendo.2023.1211954>.
- Yokota, S. *et al.* (2019) “Association of glycemic variability with left ventricular diastolic function in type 2 diabetes mellitus,” *Cardiovascular Diabetology*, 18(1). Available at: <https://doi.org/10.1186/s12933-019-0971-5>.
- Zheng, X., Tan, L. and Zhang, Y. (2024) “The impact of statin use on short-term and long-term mortality in patients with heart failure,” *Frontiers in Pharmacology*, 15. Available at: <https://doi.org/10.3389/fphar.2024.1397763>.
- Zhou, Z. *et al.* (2020) “Glycemic variability: adverse clinical outcomes and how to improve it?,” *Cardiovascular Diabetology*. BioMed Central. Available at: <https://doi.org/10.1186/s12933-020-01085-6>.
- Zhu, J. *et al.* (2023) “Impact of glycemic control on biventricular function in patients with type 2 diabetes mellitus: a cardiac magnetic resonance tissue tracking study,” *Insights into Imaging*, 14(1). Available at: <https://doi.org/10.1186/s13244-022-01357-7>.